New ABL1 Kinase Domain Mutations in BCR::ABL1‐Positive Acute Lymphoblastic Leukemia

ABSTRACT Background Since the development of the first‐generation Tyrosine Kinase Inhibitor (TKI), it has played a crucial role in the treatment of BCR::ABL1‐positive acute lymphoblastic leukemia (ALL) and chronic myeloid leukemia (CML). However, ABL1 kinase domain (ABL1 KD) mutations confer resista...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Zixuan Li, Danyue Peng, Jun Deng, Lv Xiong, Ping Yin, Jing Hu, Chenjing Qian, Lan Yao, Hua Yin, Mei Hong, Qiuling Wu
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Wiley 2024-10-01
Edice:	Cancer Medicine
Témata:	ABL1 acute lymphoblastic leukemia mutation tyrosine kinase inhibitors
On-line přístup:	https://doi.org/10.1002/cam4.70317
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!